Equity Profile

CAI

Caris Life Sciences, Inc.

Health CareBiotechnology$4.8B

Feb15Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close9:00 AM EST

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on advancing precision medicine through its innovative diagnostic solutions....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on advancing precision medicine through its innovative diagnostic solutions. Operating in the health care sector, it aims to improve patient outcomes by providing tailored treatment options based on genetic and molecular profiling.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In Q1-2026, Caris Life Sciences reported an EPS of $0.00, surprising analysts with a 100% positive surprise. The stock reacted positively, gaining 3.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the upcoming earnings report, given the company's recent positive surprises. However, the lack of analyst estimates adds uncertainty.

Bull Case

If Caris continues its trend of positive surprises, it could indicate strong operational performance and market demand for its products.

Bear Case

Conversely, any indication of revenue stagnation or failure to meet expectations could lead to a sharp decline in investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of surprises, the EPS figure will be critical in determining market sentiment and stock movement.

What is the revenue growth outlook for the upcoming quarters?

Revenue growth is essential for assessing the company's ability to sustain its business model and attract future investments.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Caris's ability to leverage its recent innovations in precision medicine, which could drive higher-than-expected revenue growth.

Supporting Evidence

Caris has consistently surprised on EPS, indicating stronger operational execution than anticipated.

The options market is pricing a larger move than historical averages, suggesting that traders expect significant news.

The company's recent advancements in diagnostics may not be fully reflected in current market expectations.

Key Risk

If the EPS exceeds $0.02, it could challenge the current bearish sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Caris can sustain its recent positive earnings surprises and revenue growth trajectory.

Bull Confirmed If

Achieving an EPS of $0.02 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.00 would confirm the bear case, signaling potential challenges in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests the stock could rise by around 0.82% on the following day, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the information.

Miss

Should the company miss expectations, history indicates a potential decline of around 6.32%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diagnostic products and their market reception.
2Management's commentary on revenue growth and future guidance.
3Insights into competitive positioning within the biotechnology sector.
4Details on partnerships or collaborations that could enhance growth.
5Any changes in operational strategy or focus areas.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Scorpio Tankers Inc.

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on advancing precision medicine through its innovative diagnostic solutions....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In Q1-2026, Caris Life Sciences reported an EPS of $0.00, surprising analysts with a 100% positive surprise. The stock reacted positively, gaining 3.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the upcoming earnings report, given the company's recent positive surprises. However, the lack of analyst estimates adds uncertainty.

Bull Case

If Caris continues its trend of positive surprises, it could indicate strong operational performance and market demand for its products.

Bear Case

Conversely, any indication of revenue stagnation or failure to meet expectations could lead to a sharp decline in investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of surprises, the EPS figure will be critical in determining market sentiment and stock movement.

What is the revenue growth outlook for the upcoming quarters?

Revenue growth is essential for assessing the company's ability to sustain its business model and attract future investments.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Caris's ability to leverage its recent innovations in precision medicine, which could drive higher-than-expected revenue growth.

Supporting Evidence

Caris has consistently surprised on EPS, indicating stronger operational execution than anticipated.

The options market is pricing a larger move than historical averages, suggesting that traders expect significant news.

The company's recent advancements in diagnostics may not be fully reflected in current market expectations.

Key Risk

If the EPS exceeds $0.02, it could challenge the current bearish sentiment and shift investor outlook positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Caris can sustain its recent positive earnings surprises and revenue growth trajectory.

Bull Confirmed If

Achieving an EPS of $0.02 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.00 would confirm the bear case, signaling potential challenges in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests the stock could rise by around 0.82% on the following day, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the information.

Miss

Should the company miss expectations, history indicates a potential decline of around 6.32%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diagnostic products and their market reception.
2Management's commentary on revenue growth and future guidance.
3Insights into competitive positioning within the biotechnology sector.
4Details on partnerships or collaborations that could enhance growth.
5Any changes in operational strategy or focus areas.